Cartesian Therapeutics, Inc. (RNAC) stock
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Earnings
Cartesian Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Cartesian Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$0.38 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | – | – | $0.46 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $78.00K | -92.9% | -$1.46 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $452.00K | +16.8% | -$1.38 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $298.00K | -99.1% | $0.50 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $1.10M | -81.2% | -$0.68 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $387.00K | – | -$1.13 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $33.45M | +543.2% | $0.54 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $5.84M | – | -$10.50 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 17, 2023before the open | $5.20M | -86.8% | -$0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $20.70M | -15.2% | -$0.05 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $39.30M | – | $0.06 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $34.00M | – | $0.08 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022before the open | $29.90M | – | $0.03 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021before the open | $24.40M | – | -$0.16 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Cartesian Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Cartesian Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Cartesian Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- Results
- Update
See a number that looks wrong?